fondaparinux has been researched along with Lupus-Erythematosus--Systemic* in 3 studies
3 other study(ies) available for fondaparinux and Lupus-Erythematosus--Systemic
| Article | Year |
|---|---|
The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome.
Limited evidence exists to guide the management of recurrent thrombosis occurring despite therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In this case series, fondaparinux, with or without an antiplatelet agent, provided an effective and safe option in three patients with thrombotic APS, all two triple and one single positive for antiphospholipid antibodies, who had recurrent venous and/or arterial thromboembolism. Rituximab was also used in all patients. Recurrent events occurred despite therapeutic anticoagulation, including at high-intensity, with warfarin and subsequent low-molecular-weight heparin. There were no major bleeding events. Adjunctive therapies used for thrombosis included catheter-directed thrombolysis and rituximab. Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Lupus Erythematosus, Systemic; Platelet Aggregation Inhibitors; Rituximab; Thrombosis; Warfarin | 2022 |
Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy.
Topics: Anticoagulants; Drug Hypersensitivity; Female; Fondaparinux; Heparin; Humans; Lupus Erythematosus, Systemic; Polysaccharides; Pregnancy; Pregnancy Complications, Hematologic; Skin Tests; Thromboembolism | 2007 |
Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
During the last decade, new anticoagulant drugs with anti-factor-Xa properties have been described (1, 2). Among them is fondaparinux that has been licensed recently. It is a pentasaccharide mimicking the site where heparin binds to antithrombin III (1). This new drug has produced very promising clinical results in the prophylaxis of venous thrombosis after orthopedic surgery (3). Here we report two different clinical situations in which fondaparinux has yielded a successful outcome: first, a patient with repeated cutaneus reaction to several different low molecular weight heparins (LMWH), and second, a patient with severe heparin-induced thrombocytopenia (HIT). We decided to use fondaparinux in both cases since it is commercially available in Spain and mostly because the absence of in vitro cross-reaction with heparins, as discussed later. Topics: Abortion, Induced; Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Autoimmune Diseases; Combined Modality Therapy; Drug Eruptions; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Lupus Erythematosus, Systemic; Polysaccharides; Postoperative Complications; Pregnancy; Thrombophilia; Thrombosis | 2003 |